Therapies targeting the programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), the immune checkpoints, have shown unprecedented rates of durable clinical responses in patients with several solid and hematological cancers (8, 9). Here, CTLA4 is linked to hematopoietic and lymphoid cell neoplasm.